Select antihypertensive medications for PA in pregnancy or preconception
STEP 1 — Gather Information
Confirm PA diagnosis (screening ARR ≥200 and PAC ≥60 pg/mL with confirmatory test), document gestational age (weeks) or pregnancy intention, current blood pressure, serum potassium, renal function, and existing antihypertensive medications. Proceed to assess pregnancy status.
STEP 2 — Rule In / Rule Out
Is the patient pregnant or actively planning pregnancy? If yes, proceed to Step 3; if no, consider standard PA treatment (mineralocorticoid receptor antagonists) — outside the scope of this skill.
STEP 3 — Classify or Stratify
Stratify by gestational age: <20 weeks gestation (or preconception) versus ≥20 weeks gestation. Also consider hypertension severity (e.g., BP ≥160/110 mmHg may require dual therapy).
STEP 4 — Decide
For <20 weeks: initiate α-methyldopa, hydralazine, or labetalol; avoid nifedipine before 20 weeks. For ≥20 weeks: may add nifedipine extended-release to the above agents. Labetalol is appropriate throughout pregnancy. If hypokalemic, add potassium supplementation (avoid with MRAs, which are contraindicated). Prescribe selected antihypertensive ± potassium supplement.
Clinical Guardrails / Mimics / Pitfalls
Do not use mineralocorticoid receptor antagonists (spironolactone, eplerenone, esaxerenone), ACE inhibitors, ARBs, or direct renin inhibitors due to teratogenicity and fetal toxicity. Avoid high-dose spironolactone for anti‑androgen effects. Monitor for hypotension, fetal growth, and serum potassium when supplementing. NSAIDs are contraindicated in later pregnancy.
Concrete Clinical Example
A 32‑year‑old woman with biochemically confirmed unilateral PA (APA) planning pregnancy presents with BP 150/95 mmHg, K+ 3.8 mmol/L, and desires conception. At preconception (0 weeks), labetalol 200 mg twice daily is started. After confirming pregnancy at 18 weeks, labetalol is continued; at 20 weeks gestation, nifedipine ER 30 mg daily is added if BP remains ≥140/90 mmHg.
Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2022, CQ 21 Point 1.